Navigation Links
Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
Date:12/4/2009

SEATTLE Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD. The findings are reported in the Nov. 4 first edition of the journal Blood.

In a retrospective study of 567 patients who underwent hematopoietic cell transplantation from matched sibling donors between 2001 and 2007, patients whose donors had been taking statins at the time of stem cell donation experienced no severe acute GVHD. About 15 percent of the stem cell donors in the study were taking statins at the time of transplant.

Normally, between 10 percent and 15 percent of transplant patients would be expected to develop severe acute GVHD, according to the study's senior author Marco Mielcarek, M.D., an assistant member of the Hutchinson Center's Clinical Research Division.

No such protection from severe acute GVHD was observed if only the patient was taking a statin, according to the study. There was some indication that protection against severe GVHD was even stronger when both patient and donor had been on statin medications, however the number of patients in this group was too small to be statistically significant.

The researchers also found that only those transplant patients with statin-treated donors who received cyclosporine-based immunosuppression therapy after transplantation were protected from severe GVHD. Patients with statin-treated donors who received a similar drug, tacrolimus, did not experience the same GVHD-protection. The study also found that the greatest statin protection occurred against severe GVHD of the gastrointestinal tract.

GVHD is a common side effect in patients who receive blood stem cell transplants from related or unrelated donors. It occurs when the transplanted cells recognize the recipient's tissues as foreign and attack the tissues. This can cause a variety of problems, including skin rashes, diarrhea and liver inflammation. Acute GVHD often occurs in the first three months after a transplant and can lead to mortality as high as 50 percent if it is severe. It can be deadly because patients require more immunosuppressive drugs to treat it, which can trigger a cascade of complications such as secondary infections.

Mielcarek, first author Marcello Rotta, M.D., a postdoctoral research fellow in the Hutchinson Center's Clinical Research Division, and colleagues undertook the study because previous research showed that statins have anti-inflammatory effects and have been found to improve control of other inflammatory diseases such as rheumatoid arthritis. Recently, studies using mouse models of stem cell transplantation have shown protection against lethal acute GVHD when the donors and recipients had been treated with statins before transplant.

The exact mechanism of how statins protect against GVHD is not known.

"In the literature, a multitude of possible mechanisms are discussed by which statins may influence immune function," Mielcarek said. "One is cell adhesion the stickiness of cells that influences how donor T cells that cause GVHD can migrate to certain target tissues. Another is how statins interfere with intracellular signaling in T cells. Statins may dampen the activity of allo-reactive T cells and prevent them from initiating the inflammatory cascade that's required to cause GVHD."

Grants from the National Institutes of Health and The Dana Foundation funded this research.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Cholesterol-lowering medicines may be effective against cancer
2. Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications
3. Cholesterol-lowering drugs may also lower PSA, but whether they cut cancer risk is still not known
4. Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research
5. Study shows cholesterol-lowering power of dietitian visits
6. Cholesterol-Lowering Statins Tied to Tendon Woes
7. Cholesterol-Lowering Drugs May Ease Irregular Heartbeat
8. New Type of Cholesterol-Lowering Drug Shows Promise
9. Many Patients Stop Taking Cholesterol-Lowering Drugs
10. Cholesterol-lowering drug linked to sleep disruptions
11. Diabetes Drugs Go Head-to-Head in Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing ... a new CEO. , Bright Pink is proud to announce Katie Thiede as their ... to a new role as Chairman of the Board and launched a national search ...
(Date:4/24/2017)... ... , ... The John P. McGovern Museum of Health and Medical Science is ... cognitive health, and share results with their physicians. Members and guests can sign up ... , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a new ... a day, Quick Care provides patients with the option to request and begin ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health ... anxiety levels in people with addiction who are served by MAP’s patient engagement ... wearable device that monitors heart and breath rates to identify anxiety levels and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: